文献速递外周动脉疾病

药物涂层球囊治疗股腘动脉病变的真实世界单中心结果

Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: A real-world single-center experience.
PubMed 文献 · J Vasc Surg · 2019-08-08

本研究回顾性分析228例接受Lutonix 0.35药物涂层球囊治疗的股腘动脉病变患者,病变以TASC C/D型为主,60%为临界肢体缺血。围手术期主要不良事件率3%,1年和2年一期通畅率分别为56%和39%,跛行患者并发症和截肢率低于临界肢体缺血患者,TASC D病变通畅率显著劣于A-C病变。

要点

  • 真实世界中DCB治疗股腘动脉病变的通畅率低于既往多中心试验。
  • TASC D病变1年一期通畅率仅29%,显著劣于TASC A-C病变的82%。
  • 跛行患者围手术期并发症和大截肢率显著低于临界肢体缺血患者。

核心结论

  • DCB治疗股腘动脉病变的真实世界临床结果劣于既往研究报道,尤其是TASC D病变。
  • 需要进一步的真实世界长期随访研究来确认这些结果。

研究设计与样本

  • 单中心真实世界回顾性分析,纳入228例接受Lutonix 0.35药物涂层球囊治疗的股腘动脉病变患者。
  • 采用Kaplan-Meier分析估计一期通畅率和保肢率,平均随访12.2个月(范围1-42个月)。

主要发现

  • 围手术期总体并发症率和死亡率分别为13%和1%,围手术期主要不良事件率为3%。
  • 64%的患者获得症状缓解(Rutherford分级改善至少1级)。
  • 1年和2年一期通畅率分别为56%和39%,保肢率分别为92%和83%。
  • 跛行患者围手术期并发症率4% vs 临界肢体缺血19%(P = .001),症状改善率76% vs 49%(P < .001),大截肢率0% vs 13%(P < .001)。
  • TASC A-C病变1年和2年一期通畅率82%和71%,TASC D病变29%和14%(P < .001)。

关键数值与推荐

  • 病变以TASC C和D型为主;跛行(Rutherford 2-3级)占40%,临界肢体缺血(Rutherford 4-5级)占60%。
  • 病变部位:61%在股浅动脉,15%在腘动脉,24%同时累及股浅动脉和腘动脉。
  • 跛行患者1年和2年保肢率均为100%,临界肢体缺血患者分别为85%和74%(P < .001)。
  • 跛行患者1年和2年一期通畅率59%和41%,临界肢体缺血患者54%和37%(P = .307)。
  • 跛行患者1年和2年辅助一期通畅率72%和52%,临界肢体缺血患者64%和46%(P = .223)。

临床怎么用

  • 真实世界中DCB治疗股腘动脉病变尤其在TASC D病变中通畅率较低,应个体化评估并加强随访。
  • 跛行患者围手术期并发症和截肢风险显著低于临界肢体缺血患者,治疗决策需考虑临床分期。

局限性

  • 单中心真实世界回顾性设计,可能存在选择偏倚。
  • 平均随访时间仅12.2个月,缺乏长期结果。
  • 样本量228例,结论需更大规模长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several multicenter industry-sponsored clinical trials reported satisfactory results in the use of drug-coated balloons (DCBs) for treatment of femoropopliteal occlusive disease. However, few single-center studies have been published to verify the outcome from real-world experience. METHODS: In this study, 228 patients treated with DCB angioplasty (Lutonix 0.35; Bard, Tempe, Arizona) were analyzed. Perioperative major adverse events (death, amputation, target lesion thrombosis or reintervention) were calculated. Kaplan-Meier analysis was used to estimate primary patency rates (based on duplex ultrasound with or without ankle-brachial index) and limb salvage rates. RESULTS: Lesions treated were primarily TransAtlantic Inter-Society Consensus (TASC) type C and D lesions. Indications included claudication (Rutherford classes 2 and 3) in 40% and critical limb ischemia (CLI; Rutherford classes 4 and 5) in 60%. Lesions treated included 61% in the superficial femoral artery, 15% in the popliteal artery, and 24% in both superficial femoral artery and popliteal artery. Mean follow-up was 12.2 months (range, 1-42 months). Overall perioperative morbidity and mortality rates were 13% and 1%. The perioperative major adverse event rate was 3%. Symptom relief (improvement of one Rutherford category or more) was obtained in 64%. Primary patency rates were 56% and 39% at 1 year and 2 years, respectively. Limb salvage rates were 92% and 83% at 1 year and 2 years. Patients with claudication had a lower rate of early perioperative complications (4% vs 19%; P = .001). Symptom improvement was 76% for claudication vs 49% for CLI (P < .001). Overall, major amputation rate was 0% for claudication vs 13% for CLI (P < .001). The primary patency rates at 1 year and 2 years were 59% and 41% for claudication vs 54% and 37% for CLI (P = .307). The assisted primary patency rates at 1 year and 2 years were 72% and 52% for claudication vs 64% and 46% for CLI (P = .223). Primary patency rates at 1 year and 2 years were 82% and 71% for TASC A to C lesions vs 29% and 14% for TASC D lesions (P < .001). Limb salvage rates at 1 year and 2 years were 100% and 100% for claudication vs 85% and 74% for CLI (P < .001). CONCLUSIONS: Clinical outcomes after DCB angioplasty in femoropopliteal lesions were inferior to what has been reported in previous studies, particularly for TASC D lesions. Further investigation from real-world experience with long-term follow-up is needed to confirm these results.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. AbuRahma AF, AbuRahma ZT, Scott G, et al. Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: A real-world single-center experience. J Vasc Surg. 2019. PMID: 31401115. doi:10.1016/j.jvs.2019.03.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。